Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers

Stroke

Volumn 39, Issue 8, 2008, Pages 2280-2287

  Montaner, Joan ^a   Perea Gainza, Mila ^a   Delgado, Pilar ^a   Ribó, Marc ^a   Chacón, Pilar ^a   Rosell, Anna ^a   Quintana, Manolo ^a   Palacios, Mauricio E ^a   Molina, Carlos A ^a   Alvarez Sabín, José ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Atherosclerosis; Cerebral ischemia; D dimer; Embolism; Natriuretic peptides; Stroke

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CALCIUM BINDING PROTEIN; CASPASE 3; CHIMERIN; D DIMER; GELATINASE B; NEUROTROPHIN 3; PROTEIN S100B; SECRETAGOGIN; UNCLASSIFIED DRUG; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; IMMUNOGLOBULIN RECEPTOR; SCGN PROTEIN, HUMAN;

AGED; ARTICLE; BLOOD SAMPLING; BRAIN; CEREBROVASCULAR ACCIDENT; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; ECHOGRAPHY; EMBOLISM; EMERGENCY WARD; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; INFARCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; STROKE PATIENT; ACUTE DISEASE; BLOOD; BRAIN EMBOLISM; BRAIN ISCHEMIA; CORONARY BLOOD VESSEL; HOSPITALIZATION; METABOLISM; MIDDLE AGED; PREDICTION AND FORECASTING; RISK FACTOR; STROKE;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; C-REACTIVE PROTEIN; CALCIUM-BINDING PROTEINS; CASPASE 3; CHIMERIN PROTEINS; CORONARY VESSELS; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; INTRACRANIAL EMBOLISM; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NEUROTROPHIN 3; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECEPTORS, IMMUNOLOGIC; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STROKE;

EID: 49849084828     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.107.505354     Document Type: Article

References (29)

1. World Health Organization. World Health Report 2002. Geneva, Switzerland: World Health Organization; 2002.
2. Hankey G, Warlow C. Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations. Lancet. 1999; 354:1457-1463.
3. Brott T, Bogousslavsky J. Treatment of acute ischemic stroke. N Engl J Med. 2000;343:710-722.
4. Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU. Epidemiology of ischemic stroke subtypes according to TOAST criteria. incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. Stroke. 2001;32: 2735-2740.
5. Ageno W, Finazzi S, Steidl L, Biotti MG, Mera V, Melzi D'Eril G, Venco A. Plasma measurement of D-dimer levels for the early diagnosis of ischemic stroke subtypes. Arch Intern Med. 2002;162:2589-2593.
6. Furie KL, Rosenberg R, Thompson JL, Bauer K, Mohr JP, Rosner B, Sciacca R, Barzegar S, Thornell B, Costigan T, Kistler JP. Thrombin generation in non-cardioembolic stroke subtypes: the Hemostatic System Activation Study. Neurology. 2004;63:777-784.
7. Tombul T, Atbas C, Anlar O. Hemostatic markers and platelet aggregation factors as predictive markers for type of stroke and neurological disability following cerebral infarction. J Clin Neurosci. 2005;12: 429-434.
8. Panteghini M. Role and importance of biochemical markers in clinical cardiology. Eur Heart J. 2004;25:1187-1196.
9. Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE III. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial: TOAST Trial of Org 10172 in acute stroke treatment. Stroke. 1993;24:35- 41.
10. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinical subtypes of cerebral infarction. Lancet. 1991;337:1521-1526.
11. Zanette EM, Roberti C, Mancini G, Pozzilli C, Bragoni M, Toni D. Spontaneous middle cerebral artery reperfusion in acute ischemic stroke: a follow-up study with transcranial Doppler. Stroke. 1995;26:430-433.
12. Grant EG, Benson CB, Moneta GL, Alexandrov AV, Baker JD, Bluth EI, Carroll BA, Eliasziw M, Gocke J, Hertzberg BS, Katanick S, Needleman L, Pellerito J, Polak JF, Rholl KS, Wooster DL, Zierler RE. Carotid artery stenosis: gray-scale and Doppler US diagnosis - Society of Radiologists in Ultrasound Consensus Conference. Radiology. 2003;229:340-346.
13. Lynch JR, Blessing R, White WD, Grocott HP, Newman MF, Laskowitz DT. Novel diagnostic test for acute stroke. Stroke. 2004;35:57- 63.
14. Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribo M, Quintana M, Alvarez-Sabin J. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation. 2003;107:598-603.
15. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339:321-328.
16. Brosnan MJ, Clark JS, Jeffs B, Negrin CD, Van Vooren P, Arribas SM, Carswell H, Aitman TJ, Szpirer C, Macrae IM, Dominiczak AF. Genes encoding atrial and brain natriuretic peptides as candidates for sensitivity to brain ischemia in stroke-prone hypertensive rats. Hypertension. 1999; 33:290-297.
17. Mäkikallio AM, Mäkikallio TH, Korpelainen JT, Vuolteenaho O, Tapanainen JM, Ylitalo K, Sotaniemi KA, Huikuri HV, Myllyla VV. Natriuretic peptides and mortality after stroke. Stroke. 2005;36:1016 -1020.
18. Nakagawa K, Yamaguchi T, Seida M, Yamada S, Imae S, Tanaka Y, Yamamoto K, Ohno K. Plasma concentrations of brain natriuretic peptides in patients with acute ischemic stroke. Cerebrovasc Dis. 2005; 19:157-164.
19. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet. 2003;362:316 -322.
20. Inoue S, Murakami Y, Sano K, Katoh H, Shimada T. Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation. J Card Failure. 2000;6:92-96.
21. Ohta Y, Shimada T, Yoshitomi H, Inoue S, Murakami Y, Shimizu H, Nakamura K, Ohta T, Katoh H, Ishibashi Y. Drop in plasma brain natriuretic peptide levels after successful direct current cardioversion in chronic atrial fibrillation. Can J Cardiol. 2001;17:415-420.
22. Shimizu H, Murakami Y, Inoue S, Ohta Y, Nakamura K, Katoh H, Sakne T, Takahashi N, Ohata S, Sugamori T, Ishibashi Y, Shimada T. High plasma brain natriuretic polypeptide level as a marker of risk for thromboembolism in patients with nonvalvular atrial fibrillation. Stroke. 2002; 33:1005-1010.
23. Tohgi H, Kawashima M, Tamura K, Suzuki H. Coagulation-fibrinolysis abnormalities in acute and chronic phases of cerebral thrombosis and embolism. Stroke. 1990;21:1663-1667.
24. Nagao T, Hamamoto M, Kanda A, Tsuganesawa T, Ueda M, Kobayashi K, Miyazaki T, Terashi A. Platelet activation is not involved in acceleration of the coagulation system in acute cardioembolic stroke with nonvalvular atrial fibrillation. Stroke. 1995;26:1365-1368.
25. Falcone C, Emanuele E, D'Angelo A, Buzzi MP, Belvito C, Cuccia M, Geroldi D. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol. 2005;25:1032-1037.
26. Cerebral Embolism Task Force. Cardiogenic brain embolism. Arch Neurology. 1986;43:71-84.
27. Lovett JK, Coull AJ, Rothwell PM. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology. 2004; 62:569-573.
28. Lee-Lewandrowski E, Van Cott EM. Evaluation of the Biosite Triage® quantitative whole blood D-dimer assay and comparison with the bioMerieux VIDAS® D-dimer exclusion test: validation and utility for use in the central laboratory and at the point of care. Point Care. 2005; 4:133-137.
29. Vanderheyden M, Bartunek, Claeys G, Manoharan G, Beckers JF, Ide L. Head to head comparison of N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in patients with/without left ventricular systolic dysfunction. Clin Biochem. 2006;39:640-645.